Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Indiana
Clinical trial register · United States · industry-sponsored

Clinical Trials in Indiana, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9125 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Oct 2026, 03:16 UTC
9125
Studies in scope
industry-sponsored, all four open statuses
4951
Recruiting now
open to new participants
2192
Lead sponsors
across recruiting studies
Top states
California 84 Florida 69 Colorado 41 Texas 40 Massachusetts 38
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in Indiana

13 of 9125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
NCT06956690Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer
Hummingbird Bioscience
Phase 1/2
180
California, Indiana, Michigan, Texas
2025-12-17
Recruiting
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
NCT07205822Breast Cancer
AstraZeneca
Phase 3
100
Florida, Indiana, Nebraska, New York, Texas, Washington
2025-10-30
Recruiting
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
NCT07211178Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer
Tempus AI
Observational
900
Alabama, California, Florida, Illinois, Indiana, Michigan, Missouri, Nevada
2025-10-27
Recruiting
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT06401421Breast Cancer
Exact Sciences Corporation
Observational
1,800
Alaska, California, Colorado, Florida, Illinois, Indiana, Kansas, Kentucky
2024-06-07
Recruiting
BostonGene and Exigent Genomic INsight Study
NCT06272864Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
BostonGene
Observational
400
Arkansas, California, Indiana, New Mexico, Oklahoma, Texas, Washington
2024-04-08
Recruiting
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT06072612Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic
BriaCell Therapeutics Corporation
Phase 3
404
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kansas
2023-12-05
Active, closed
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT05787587Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
IDEAYA Biosciences
Phase 1
216
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2023-04-18
Recruiting
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
NCT05735080Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Incyclix Bio
Phase 1/2
150
Florida, Georgia, Indiana, Massachusetts, Michigan, New York, North Carolina, Ohio
2023-03-28
Recruiting
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT05366881Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
Adela, Inc
Observational
7,000
California, Florida, Georgia, Indiana, Kentucky, Minnesota, Ohio, Oregon
2022-05-03
Recruiting
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
NCT05216432PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer
Relay Therapeutics, Inc.
Phase 1
930
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Massachusetts
2021-12-08
Active, closed
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
AstraZeneca
Phase 3
927
Arkansas, California, Connecticut, Indiana, Kentucky, Louisiana, Minnesota, Nevada
2021-10-25
Active, closed
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
Eli Lilly and Company
Phase 1
379
Arizona, Arkansas, California, Florida, Georgia, Indiana, Maryland, Massachusetts
2019-12-10
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/state/indiana

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,125 studies in total at the last sync on 08 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies with a site in Indiana that also match the filters currently applied.

How many clinical trials are recruiting in Indiana?

9 of the 13 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Indiana), 13 studies
PhaseStudiesRecruitingShare
Observational4430.8%
Phase 34230.8%
Phase 13123.1%
Phase 1/22215.4%

Most active sponsors

Lead sponsors with the most studies (Indiana)
Lead sponsorStudiesRecruiting
AstraZeneca21
Adela, Inc11
BostonGene11
BriaCell Therapeutics Corporation11
Eli Lilly and Company10
Exact Sciences Corporation11
Hummingbird Bioscience11
IDEAYA Biosciences10
Incyclix Bio11
Merck Sharp & Dohme LLC10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.